William Blair analyst Andrew Brackmann has reiterated their bullish stance on BFLY stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Brackmann has given his Buy rating due to a combination of factors related to Butterfly Network’s current performance and long-term positioning. He notes that fourth-quarter revenue growth met and slightly exceeded consensus expectations, suggesting that the core point-of-care ultrasound (POCUS) market is at least stable relative to prior guidance reductions. He also expects upcoming company presentations and formal guidance to provide more detail and potential confirmation of this trajectory. Overall, the latest update is seen as in line with what management had previously communicated and does not alter his constructive view of the business.
At the same time, Brackmann emphasizes that the investment case extends well beyond near-term POCUS trends. He believes Butterfly’s ultrasound-on-chip technology offers a differentiated platform with a broad range of monetization opportunities outside its initial market, effectively evolving the company into a larger and more compelling growth story. As the company delivers additional execution milestones and validates more use cases, he sees the business model becoming less risky and the stock having meaningful upside potential. While he acknowledges risks such as the pace of adoption in medicine, competitive pressures, timing of new opportunities, IP-related noise, and ongoing cash burn, he views these as manageable relative to the upside, supporting his continued Buy recommendation.
Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Exact Sciences, and Adaptive Biotechnologies. According to TipRanks, Brackmann has an average return of 35.6% and a 67.21% success rate on recommended stocks.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $4.50 price target.